Novel Glaucoma Diagnostics

Description

The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases

Conditions

Glaucoma, Macular Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases

Novel Diagnostics for Ocular Structure

Novel Glaucoma Diagnostics

Condition
Glaucoma
Intervention / Treatment

-

Contacts and Locations

Philadelphia

Wills Eye Hospital, Philadelphia, Pennsylvania, United States, 19107

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Ability to provide informed consent and to understand the study procedures
  • * Healthy volunteers
  • * Age related macular degeneration (AMD), diabetic retinopathy, central serous chorioretinopathy, and/or glaucoma or glaucoma suspects
  • * (AD Sub-Study ONLY): Subjects diagnosed with AD or MCI.
  • * Any medical treatment (e.g., chronic corticosteroid, hydroxychloroquine, chloroquine, thioridazine, canthaxanthine) or conditions that affect VF (e.g., stroke) and retinal thickness other than glaucoma.
  • * Strabismus, nystagmus, or any condition that prevents fixation.
  • * Presence of any media opacities that hinders clinical view of the fundus, and any intraocular non-glaucomatous abnormality
  • * History of ocular trauma or intraocular surgery other than uncomplicated glaucoma interventions or cataract extraction at least 3 months previous to participating in the study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

Wills Eye,

Joel S Schumann, MD, STUDY_CHAIR, Wills Eye Hospital

Study Record Dates

2029-07-31